Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Closed 05-15 16:00:00 EDT

0.8500

-0.0229

-2.62%

盘后0.8401

-0.0099-1.16%

19:48 EDT

High0.8701	Low0.8418	Vol856.10K
Open0.8700	D1 Closing0.8729	Amplitude3.24%
Mkt Cap98.71M	Tradable Cap96.90M	Total Shares116.13M
T/O729.68K	T/O Rate0.75%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.85,"timestamp":1778875200000,"preClose":0.8729,"halted":0,"volume":856099,"hourTrading":{"tag":"盘后","latestPrice":0.8401,"preClose":0.85,"latestTime":"19:48 EDT","volume":21652,"amount":18370.7307,"timestamp":1778888898790,"change":-0.0099,"changeRate":-0.011647,"amplitude":0.019765},"delay":0,"changeRate":-0.02623439111009283,"floatShares":113999999,"shares":116128162,"eps":-0.300019,"marketStatus":"Closed","change":-0.0229,"latestTime":"05-15 16:00:00 EDT","open":0.87,"high":0.8701,"low":0.8418,"amount":729683.997264,"amplitude":0.032421,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.300019,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.8729,"preHourTrading":{"tag":"盘前","latestPrice":0.86,"preClose":0.8729,"latestTime":"08:39 EDT","volume":6526,"amount":5626.0659052,"timestamp":1778848750277,"change":-0.0129,"changeRate":-0.014778,"amplitude":0.000115},"postHourTrading":{"tag":"盘后","latestPrice":0.8401,"preClose":0.85,"latestTime":"19:48 EDT","volume":21652,"amount":18370.7307,"timestamp":1778888898790,"change":-0.0099,"changeRate":-0.011647,"amplitude":0.019765},"volumeRatio":1.276461},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2635472504","title":"Oncolytics net loss more than doubled to $9.24 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635472504","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635472504?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:32","pubTimestamp":1778790720,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech posted a net loss of USD 9.24 million for the quarter ended March 31, 2026, widening from USD 4.71 million a year earlier.Research and development expense climbed 62.57% to USD 4.55 million, driven by higher personnel costs and startup spending for a randomized Phase 2 second-line metastatic colorectal cancer study.General and administrative expense more than doubled to USD 4.73 million, on higher public company-related costs tied to investor relations activity and professional fees related to the Domestication.Cash and cash equivalents edged up to USD 5.49 million; operating cash outflow widened to USD 7.29 million.Fast Track Designation was granted in 2026 for pelareorep with bevacizumab and FOLFIRI in KRAS-mutant, microsatellite-stable second-line mCRC; an open market sale agreement with Jefferies allows up to USD 75 million of common stock sales.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL9Lr6HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633696941","title":"Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633696941","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633696941?lang=en_us&edition=fundamental","pubTime":"2026-05-05 22:55","pubTimestamp":1777992958,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Oncolytics Biotech today and set a price target of $5.00. According to TipRanks, Messer ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955426","title":"BRIEF-Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955426","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955426?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:09","pubTimestamp":1777900170,"startTime":"0","endTime":"0","summary":"BRIEF-Oncolytics Biotech Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal CancerMay 4 (Reuters) - Oncolytics Biotech Inc ONCY.O:ONCOLYTICS BIOTECH REPORTS DURABLE RESPONSES IN SECOND","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955669","title":"Oncolytics says pelareorep combo shows 19.5-month response duration in Phase 2 mCRC study","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955669","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955669?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899635,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech disclosed new durability results from REO 022 in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer, with results already presented as new data in its update.Pelareorep-based combination therapy showed sustained tumor response versus typical outcomes in this treatment setting.Response activity also compared favorably with standard care benchmarks, supporting a stronger clinical benefit profile.Company is enrolling a randomized Phase 2 study of pelareorep with FOLFIRI and bevacizumab in the same population.FDA discussions are underway on a potential accelerated approval path, centered on response durability and time-to-event measures from the ongoing trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL3pJC2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","SG9999014005.SGD","NDAQ","BK4585","BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014021.USD","BK4112","ONCY","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955127","title":"Oncolytics Biotech Inc - 2L Kras-Mutant Mss Mcrc Demonstrates 3-4X Improvement in Duration of Response VS. Historical 4-6 Month Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955127?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955119","title":"Oncolytics Biotech Inc - Pelaeoreorep Combination Shows 19.5-Month Median Duration of Response in 2L Kras-Mutant Mss Mcrc","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955119?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955114","title":"Oncolytics Biotech Inc - Engaged With FDA on Accelerated Approval Pathway for 2L Ras-Mutant Mss Mcrc","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955114?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630898583","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (ONCY) and Agilon Health (AGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630898583","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630898583?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:00","pubTimestamp":1777384835,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY) and Agilon Health (AGL)....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-oncolytics-biotech-oncy-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-oncolytics-biotech-oncy-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4539","HCSG","LU0128526141.USD","BK4137","BK4588","XLV","ONCY","BK4139","BK4581","BK4585","AGL","LU0029874061.USD","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630392596","title":"Oncolytics says in alignment with FDA following pelareorep Type C meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630392596","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630392596?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:19","pubTimestamp":1777295945,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced that a Type C meeting with the FDA has resulted in alignment on the design of a pivotal clinical study to support appro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-says-in-alignment-with-fda-following-pelareorep-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-says-in-alignment-with-fda-following-pelareorep-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4139","ONCY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630399322","title":"Oncolytics Biotech Inc - Announces Alignment With FDA on Pivotal Anal Cancer Study - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630399322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630399322?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:19","pubTimestamp":1777292384,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A07E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396005","title":"Oncolytics aligns with FDA on pivotal pelareorep anal cancer trial design","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396005?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:14","pubTimestamp":1777292084,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech aligned with FDA on design of a pivotal trial for pelareorep in unresectable metastatic squamous cell carcinoma of anal canal.Study will use a randomized controlled design intended to support accelerated approval and full approval from a single trial.Plan targets patients whose disease progressed after standard first-line therapy, a setting with no FDA-approved treatment options.Prior study results in second-line or later disease were already presented, showing signs of more durable responses and improved survival versus current standard of care.Company expects to incorporate FDA feedback into final protocol for the pivotal study.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL9Jv7B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4588","SG9999014013.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4112","LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","BK4585","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628824927","title":"Top News Today: Stocks Rise Amid Hopes for Further U.S.-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2628824927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628824927?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:31","pubTimestamp":1776371460,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose as another up-tick in oil prices stoked inflation concerns.COMMODITIES: Oil futures settled higher after U.S. officials indicated a tightening of the blockade of ships in and out of Iranian ports.Netflix Chair Reed Hastings to Leave Board in June. Netflix Chairman and co-founder Reed Hastings will step down from the company's board after his term expires in June, the streaming giant said Thursday.Cutting Prices on Doritos Has Paid Off, PepsiCo Says. In February, PepsiCo said it would cut prices on some of its chips and snacks by as much as 15%, in a bid to woo cost-conscious consumers back to snacks like Lay's potato chips and Doritos. The company found affordability was a big reason why consumers held back from purchases. In some markets, the price of some large bags of chips cost well over $6.Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales. Abbott attributed the lower outlook to its acquisition of cancer-diagnostics company Exact Scie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a82f876c315cf798ee69d53113741722","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ51526630.SGD","LU1814569148.SGD","CCNE","LU1548497426.USD","IE00BKPKM429.USD","LU1429558221.USD","CARM","LU0868494708.USD","NFXL","FITB","NECB","PKBK","CWBC","LU0097036916.USD","LU1674673428.USD","NFLX","LU0234570918.USD","RF","NFLY","NROM","LU0106261372.USD","LU2461242641.AUD","MPU","LU1880398554.USD","LU0082616367.USD","LU1668664300.SGD","LU1989764664.SGD","NFLU","NFXS","BK4561","AAME","ALLY","BK4207","LU1064131342.USD","LU1366192091.USD","LU0882574139.USD","SGXZ23171101.USD","BK4548","BK4585","LU1035775433.USD","NFLW","BMI","LU0417517546.SGD","LU0106831901.USD","LU2237957902.USD","ONCY","LU0256863811.USD","NFLP","LU1791807156.HKD","LU0077335932.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625602278","title":"Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (ONCY) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625602278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625602278?lang=en_us&edition=fundamental","pubTime":"2026-04-07 05:50","pubTimestamp":1775512205,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY) and Neurocrine (NBIX). O...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-oncolytics-biotech-oncy-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-oncolytics-biotech-oncy-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823416689.USD","LABU","LU2065171402.SGD","LU2065170008.USD","BK4139","LU2324357040.USD","LU0320765992.SGD","LU0029874061.USD","BK4137","HCSG","BK4588","LU2065171311.SGD","BK4581","LU0154245673.USD","XBI","BK4585","LU0128526141.USD","LU0154245756.USD","NBIX","ONCY","LU0109394709.USD","LU2065169927.USD","LU0889565916.HKD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625097506","title":"Oncolytics Biotech signs Jefferies ATM equity sale agreement for up to $75 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2625097506","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625097506?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:13","pubTimestamp":1775506414,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech entered an at-the-market equity distribution agreement with Jefferies for up to USD 75 million of common stock.Jefferies will sell shares from time to time based on company instructions.Sales will be made off a Form S-3 shelf registration statement declared effective April 3, 2026.Agent commission set at up to 3% of gross proceeds.Net proceeds earmarked for pelareorep clinical development, related R&D, operating costs, working capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLc9Nmqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625751609","title":"Oncolytics Biotech Inc - to Offer and Sell Common Stock up to $75 Mln Through Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625751609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625751609?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:13","pubTimestamp":1775506388,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40N025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625142603","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali","url":"https://stock-news.laohu8.com/highlight/detail?id=2625142603","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625142603?lang=en_us&edition=fundamental","pubTime":"2026-04-07 01:51","pubTimestamp":1775497861,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, DenaliWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL6N40P09M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07766","TLA","ELAB","BKNG","TSN","AMD","PRAX","ADM","CVNA","TSLW","XOM","TSLY","ONCY","TSLS","VLO","LGN","CAR","QCOM","CVNX","ATMU","NVD","TSLR","WLK","DNLI","EXPE","NVDD","OXY","CVX","DOW","PFSA","AESI","TSLI","WTBA","FAF","NVDA","TSLA","SLNO","NSC","DVN","TSLZ","IDYA","AVGO","RKT","DIPS","AGPU","IBRX","TSLT","CVNY","LYB","KTOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625670663","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget","url":"https://stock-news.laohu8.com/highlight/detail?id=2625670663","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625670663?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:44","pubTimestamp":1775490252,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis BudgetWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL6N40P0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDY","ELAB","QCMU","BKNG","TSN","AMD","PRAX","ADM","CVNA","AMYY","XOM","ONCY","VLO","LGN","CAR","QCOM","ATMU","KTUP","WLK","EXPE","AVGG","CVX","OXY","QCMD","DOW","PFSA","QCML","AESI","WTBA","ANV","FAF","NVDA","AMDD","AVGU","SLNO","AMDG","AMDL","DVN","IDYA","AVGO","RKT","DIPS","AGPU","IBRX","SNVD.UK","AMDU","AMUU","LYB","KTOS","AMDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625672933","title":"BUZZ-Oncolytics rises as it schedules FDA talks on anal cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625672933","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625672933?lang=en_us&edition=fundamental","pubTime":"2026-04-06 22:02","pubTimestamp":1775484177,"startTime":"0","endTime":"0","summary":"BUZZ-Oncolytics rises as it schedules FDA talks on anal cancer drug** Shares of biotech firm Oncolytics Biotech ONCY.O rise 2% to $0.97** Co says it will meet the FDA on April 16 to discuss a possible approval path for its experimental anal cancer drug pelareorep** This rare cancer starts in anal canal and few options exist once standard treatments fail** Co says it plans to propose a singlearm study combining pelareorep with a type of cancer immunotherapy in patients who have no approved alternatives** Earlier study showed about a 30% tumor response rate lasting around 17 months, compared with 10%–14% and about 9.5 months for existing options, co says** Including session's move, stock up ~12% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL4N40P0PL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625603672","title":"Oncolytics schedules FDA meeting for pelareorep registrational path","url":"https://stock-news.laohu8.com/highlight/detail?id=2625603672","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625603672?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:56","pubTimestamp":1775483771,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced it has scheduled a Type C meeting with the FDA on April 16, to discuss a potential registrational development path for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-schedules-fda-meeting-for-pelareorep-registrational-path-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-schedules-fda-meeting-for-pelareorep-registrational-path-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","LABU","ONCY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625088671","title":"Oncolytics schedules FDA Type C meeting on single-arm registrational pathway for pelareorep in anal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625088671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625088671?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:00","pubTimestamp":1775480443,"startTime":"0","endTime":"0","summary":"Oncolytics scheduled Type C meeting with FDA for April 16, 2026 to discuss registrational path for pelareorep in squamous cell anal carcinoma.Discussion set to cover potential single-arm pivotal study of pelareorep plus checkpoint inhibitor in second-line or later patients, targeting about 60-70 enrollment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL8BYSS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","BK4139","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","BK4585","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","ONCY","NDAQ","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0301},{"period":"1month","weight":-0.1442},{"period":"3month","weight":-0.1765},{"period":"6month","weight":-0.1607},{"period":"1year","weight":0.6851},{"period":"ytd","weight":-0.0013}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0773},{"period":"3month","weight":0.0974},{"period":"6month","weight":0.1135},{"period":"1year","weight":0.2733},{"period":"ytd","weight":0.0972}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.024604},{"month":5,"riseRate":0.25,"avgChangeRate":-0.009139},{"month":6,"riseRate":0.285714,"avgChangeRate":0.190573},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction